Right Patients,
Right Time
Our off-the-shelf approach allows us to investigate our precision vaccines alongside the standard of care for a given cancer type at any timepoint in a patient’s cancer treatment journey.
The accelerated regulatory route enabled by our MHRA-awarded Innovative Licensing and Access Pathway (ILAP) passport, has allowed us to initiate our
first-in-human VISTA study: a randomised, placebo-controlled, double-blind phase 1/2a trial in resectable oesophageal adenocarcinoma. This is a population with high unmet need, with half of patients experiencing recurrence within 2-3 years of surgery. Our off-the-shelf design means we can intervene at the earliest opportunity, with the first dose given before the tumour is surgically removed.
VISTA is designed to provide rapid proof-of-concept for our Precision ImmunomicsTM antigen discovery platform and our proprietary vector platform. We are actively exploring partnership and collaboration opportunities to accelerate expansion into an initial 4 additional cancers covering a $45 billion addressable market.
